Table 1.
Age | Sex | TNM stage | Histology of tumor | Drug regimen of HIPEC | Duration of HIPEC (min) | ECOG | HIPEC temperature (°C) | Time of surgery (h) | Following time (yr) and results |
49 | Male | T4aN1M0 | Poorly-differentiated adenocarcinoma | 5-Fu cisplatin | 60 | 1 | 43 | 3 | 1, alive |
56 | Male | T3N2M0 | Moderately-differentiated adenocarcinoma | 5-Fu cisplatin | 60 | 2 | 43 | 3.5 | 1.5, alive |
67 | Female | T4N2M0 | Poorly-differentiated adenocarcinoma | 5-Fu cisplatin | 60 | 0 | 43 | 3.8 | 1, dead |
53 | Male | T3N1M0 | Poorly-differentiated adenocarcinoma | 5-Fu cisplatin | 60 | 1 | 43 | 4 | 1.2, dead |
62 | Male | T4bN0M0 | Moderately-differentiated adenocarcinoma | 5-Fu cisplatin | 60 | 2 | 43 | 3 | 0.5, alive |
ECOG: Eastern Cooperative Oncology Group; HIPEC: Hyperthermic intraperitoneal chemotherapy.